Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.

[1]  T. Stobdan,et al.  Endothelial nitric oxide synthase gene haplotypes and circulating nitric oxide levels significantly associate with risk of essential hypertension. , 2008, Free radical biology & medicine.

[2]  Anne L. Taylor,et al.  Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. , 2007, Journal of cardiac failure.

[3]  D. Angus,et al.  Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure , 2005, Circulation.

[4]  H. Snieder,et al.  Influence of the eNOS gene on development of blood pressure and left ventricular mass: Longitudinal findings in multiethnic youth , 2005, Pharmacogenetics and genomics.

[5]  J. Tanus-Santos,et al.  Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men , 2005, Pharmacogenetics and genomics.

[6]  J. Tanus-Santos,et al.  Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. , 2005, Nitric oxide : biology and chemistry.

[7]  K. Kawecka-Jaszcz,et al.  Ambulatory blood pressure, left ventricular mass and vascular phenotypes in relation to the endothelial nitric oxide synthase gene Glu298Asp and intron 4 polymorphisms in a population-based family study , 2005, Journal of Human Hypertension.

[8]  J. Stamler,et al.  NO/redox disequilibrium in the failing heart and cardiovascular system. , 2005, The Journal of clinical investigation.

[9]  G. MacGowan,et al.  Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[10]  J. Hare.  Nitroso-redox balance in the cardiovascular system. , 2004, The New England journal of medicine.

[11]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[12]  Anne L. Taylor.  The African-American heart failure trial (A-HeFT): rationale and methodology☆ , 2003 .

[13]  G. MacGowan,et al.  Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure , 2003, Circulation.

[14]  D. Dudley,et al.  Haplotype-Specific Effects on Endothelial NO Synthase Promoter Efficiency: Modifiable by Cigarette Smoking , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Justin S. W. Taylor,et al.  Racial Differences in Responses to Drug Treatment , 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[16]  J. Tanus-Santos,et al.  Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. , 2001, Pharmacogenetics.

[17]  I. Bata,et al.  Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. , 2001, American heart journal.

[18]  Richard T. Lee,et al.  Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice , 2001, Circulation.

[19]  J. Bauer,et al.  Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. , 2001, Trends in pharmacological sciences.

[20]  J. Peleska,et al.  Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. , 2001, Biochemical and biophysical research communications.

[21]  T. Shinke,et al.  Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. , 2000, Circulation.

[22]  J. Moss,et al.  Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Hingorani,et al.  A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK. , 1999, Circulation.

[24]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[25]  O. Carretero,et al.  Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. , 1999, Hypertension.

[26]  J. Bronzwaer,et al.  Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. , 1999, Circulation.

[27]  H. Drexler.  Nitric oxide synthases in the failing human heart: a doubled-edged sword? , 1999, Circulation.

[28]  K. Nakao,et al.  T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. , 1999, Circulation.

[29]  G. Kojda,et al.  Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[30]  L. Almasy,et al.  Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[31]  A. Takeshita,et al.  Role of Myocyte Nitric Oxide in β-Adrenergic Hyporesponsiveness in Heart Failure , 1997 .

[32]  J. Balligand,et al.  Nitric oxide and cardiac function. , 1996, Circulation research.

[33]  W. Schmitz,et al.  Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. , 1996, Journal of molecular and cellular cardiology.

[34]  S. Scherer,et al.  Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. , 1993, The Journal of biological chemistry.

[35]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[36]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[37]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .